Investor Center


Press Release

Printer Friendly Version  View printer-friendly version
<< Back
Bellicum to Report Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 8, 2016

HOUSTON--(BUSINESS WIRE)--Aug. 1, 2016-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Monday, August 8, 2016 at 5:00 p.m. EDT to report its second quarter 2016 financial results and provide a corporate update.

To access the call, participants should dial (855) 779-9069 (U.S. domestic) and (631) 485-4863 (international) at least 10 minutes prior to the start of the call, using Conference ID number 53430483. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will be available for replay in the Investor and Media section of the Bellicum website for at least two weeks following the call.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals, Inc.

Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, 832-384-1116
CFO
amusso@bellicum.com
or
Media:
BMC Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com